Off-label use of rFVIIa and its clinical effectiveness: results from a Scottish national audit

被引:0
|
作者
Gallipoli, P.
Robertson, M.
Tait, R. C.
机构
[1] Glasgow Royal Infirm, Dept Haematol, Glasgow G4 0SF, Lanark, Scotland
[2] Royal Alexandra Hosp, Dept Haematol, Paisley, Renfrew, Scotland
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
248
引用
收藏
页码:85 / 85
页数:1
相关论文
共 50 条
  • [21] Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China
    Xie, Lu
    Guo, Wei
    Wang, Ye
    Yan, Taiqiang
    Ji, Tao
    Xu, Jie
    BMC CANCER, 2018, 18
  • [23] Off-label Use from the Perspective of pharmaceutical Companies
    Schloebe, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 50 - 50
  • [24] Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
    Lu Xie
    Wei Guo
    Ye Wang
    Taiqiang Yan
    Tao Ji
    Jie Xu
    BMC Cancer, 18
  • [25] Results from 2010 NAMS Survey on use of Compounded and Off-label Hormone Products
    Gass, Margery
    Stuenkel, Cynthia
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (12): : 1359 - 1359
  • [26] French national cohort of first use of dalbavancin: A high proportion of off-label use
    Dinh, Aurelien
    Duran, Clara
    Pavese, Patricia
    Khatchatourian, Lydie
    Monnin, Boris
    Bleibtreu, Alexandre
    Denis, Eric
    Etienne, Cedric
    Rouanes, Nicolas
    Mahieu, Rafael
    Bouchand, Frederique
    Davido, Benjamin
    Lotte, Romain
    Cabaret, Philippe
    Camou, Fabrice
    Chavanet, Pascal
    Assi, Assi
    Limonta, Silvia
    Lechiche, Catherine
    Riou, Raphaelle
    Courjon, Johan
    Illes, Gabriela
    Lacassin-Beller, Flore
    Senneville, Eric
    Adjodah, Chandra
    Baclet, Nicolas
    Bouchard, Odile
    Boutoille, David
    Brunin, Guillaume
    Carbognani, Daniel
    Delobel, Pierre
    Ferrand, Helene
    Imbert, Yves
    Leautez-Nainville, Sophie
    Le Moing, Vincent
    Loutfi, Bouchra
    Mrozek, Natacha
    Rouzic, Nicolas
    Talarmin, Jean-Philippe
    Tattevin, Pierre
    Weyrich, Pierre
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (05) : 668 - 672
  • [27] EFFECTIVENESS OF OFF-LABEL USE OF BEVACIZUMAB IN RECURRENT OVARIAN AND METASTATIC BREAST CANCER
    Arroyo Patricia, Araque
    Santos Pedro, Cuesta
    Martin Monica, Ferrit
    Diez Barbara, Cancela
    Ana Maria, Alanon Pardo
    Juan Carlos, Valenzuela Gamez
    Miguel Angel, Calleja Hernandez
    ATENCION FARMACEUTICA, 2012, 14 (03): : 167 - 173
  • [28] Analysis of effectiveness of off-label use of Bevacizumab in recurrent breast and ovarian cancer
    Araque, P.
    Alanon, A. M.
    Carreras, M. J.
    Peran, L.
    Fernandez, M. A.
    Calleja, M. A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 451 - 451
  • [29] Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: A Multicenter Study
    Michaud, Martin
    Lidove, Olivier
    Bienvenu, Boris
    Chiche, Laurent
    Urbanski, Geoffrey
    JOINT BONE SPINE, 2020, 87 (02) : 179 - 180
  • [30] Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics
    Hao, Guo-Xiang
    Song, Lin-Lin
    Zhang, Dong-Feng
    Su, Le-Qun
    Jacqz-Aigrain, Evelyne
    Zhao, Wei
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (02) : 274 - 284